Analysts: Cytokinetics Incorporated (NASDAQ:CYTK) Market Cap To Touch 1.29 billion

Cytokinetics Incorporated (NASDAQ:CYTK) closed the previous session at $9.25, up by 0.86 or 10.25% higher on its price over the last trading period. Shares of the company have traded -0.96% down in the last 5 days, with the price reaching as high as $9.34 since 11/19/19. The stock however has recovered +17.24% since hitting 5-day low of $7.89. The CYTK stock is -25.64% lower than the $12.44 top value it marked over a period of month. Cytokinetics Incorporated (NASDAQ:CYTK) has a 52-week price range of $5.75- $14.94. The stock is 46.36% up year-to-date. Can CYTK go on to record further gains or will the drop below $8.39 be witnessed again in coming days?

In comparison, let’s see recent movement of other stocks the recent users of Yahoo Finance’s stock information-accessing system have also looked at before they searched Cytokinetics Incorporated (CYTK). Shares of ArQule Inc. (NASDAQ:ARQL) changed $0.87 or a gain of 11.46% to close at $8.46, while the stock of Eiger BioPharmaceuticals Inc. (NASDAQ:EIGR) gained nearly 3.65% in the last session to close at price of $11.65. Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) advanced $0.26 in value, or 0.25% to see deals exchanging hands at $103.77 in the last period. Trevena Inc. (NASDAQ:TRVN) dropped $0.0 or about -0.01 to see its shares trade at $0.68.

What do analysts say about the Cytokinetics Incorporated (NASDAQ:CYTK) stock in terms of estimates, with 6 ratings?. The analysts’ current recommendation for the stock is a Buy, versus Buy a month ago and a Buy rating 3-month ago. The total number of analysts who have rated CYTK as a buy is 5, with just 0 of 6 recommending it as a Sell. 6 analysts of the 0 rated it as underweight; while 1 advised Hold and a further 0 say the stock is Overweight.

Lets us now look at some key statistics for the company and see what they tell us about its books. Cytokinetics Incorporated has a market valuation of $542.14 million, with its Enterprise Value at $382.25 million. The enterprise value (EV) is -41.83% off Cytokinetics Incorporated’s market cap. Shares traded in the last session stood at 2424799 while the average trading volume is 608.97K. Insiders own 0.60% of the shares institutions own 80.80% as outstanding shares currently stand at 58.61 million. When we look at the 20-day simple moving average, CYTK is -8.00%, while that moves to -17.45% over its 50-day SMA and the SMA200 is -10.55%.

When we look at the consensus estimate for CYTK shares, we find that Wall Street analysts have given the average target price of $22.00. The earnings estimate for the current quarter is -0.48, higher than the -0.54 expected for the next quarter. The stock has earnings per share estimate ranging between a low of -0.54 and a high of -0.38, with the coefficient variance at -12.93. For this fiscal year, the estimate climbs to 6.00 versus the 6.00 expected for the next year. CYTK has current-year EPS range between a low of -2.13 and a high of -1.85, with the coefficient variance at -5.13.

The company’s trailing 12-month price-to-sales ratio is 17.49.

For the fiscal quarter ending 12/30/2018, Cytokinetics Incorporated had revenue of $7.19M. The earnings per share for the most recent quarter were -0.48. The EPS for the recent quarter beat consensus estimates by $0.04 per share after analysts had predicted -$0.52. EPS posted in 1 out of the last 4 quarters have beaten analysts’ estimates.

The investor community is excited about the CYTK stock, with the Barchart 72% Sell showing that the stock could be headed for a massive downtrend. The stock’s 1-month chart already shows that the stock is -18.57% down and -33.64% lower in the last 3 months. Its 12-month performance is showing the stock trending higher by 37.04%. There might be a slight pullback as $9.62 is the first resistance point and if crossed $10.00 should come in play as the second resistance level. CYTK could see support around 8.59 and will later test the 7.94 support.